Biopharma Healthcare Provider Leads 
pharmaphorum
DECEMBER 18, 2022
However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcare providers (HCPs) as consumers. This, once again, leads to abandonment caused by patient out-of-pocket costs as a critical driver in non-adherence.
PM360
AUGUST 9, 2022
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.
Impetus Digital
MARCH 15, 2024
Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017).
PM360
AUGUST 24, 2023
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.
Clarify Health
MAY 19, 2020
Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., sales, medical science liaisons, etc.).
Legacy MEDSearch
MAY 19, 2023
Through this collaboration, healthcare providers are able to access clinically relevant heart rhythm analyses and actionable reports via PaceMateLIVE to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and drive improvements to patient care and clinical outcomes.
Clarivate
FEBRUARY 28, 2023
Degeneration of the retinal ganglion cells causes rapidly progressing vision loss, leading to permanent (non-painful) blindness within a year. The Incidence and Prevalence Database (IPD) , a Cortellis solution, provides information on LHON prevalence and primary mutations, morbidity and mortality rates. 2017.02.001 [3] Filatov A et al.
Expert insights. Personalized for you.
81 
Let's personalize your content